Specifically, using our TIL-PDX model of human lung adenocarcinoma (TIL-PDX-LUAD), we show profound tumor regression when treated with a combination immunotherapy consisting of IL-15 stimulation and PD-1 blockade. Here, IL15 is linked to neoplasm.